Mechanism of action potential prolongation by RP 58866 and its active enantiomer, terikalant: Block of the rapidly activating delayed rectified K+ current, I(Kr)

Circulation

Volumn 94, Issue 11, 1996, Pages 2938-2946

  Jurkiewicz, Nancy K ^a   Wang, Jixin ^a   Fermini, Bernard ^a   Sanguinetti, Michael C ^b   Salata, Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

action potentials; antiarrhythmia agents; dofetilide; electrophysiology; potassium

Indexed keywords

DOFETILIDE; TERIKALANT;

ACTION POTENTIAL; AFTERHYPERPOLARIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; NONHUMAN; PACEMAKER; POTASSIUM CURRENT; PRIORITY JOURNAL;

EID: 0029819368     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.2938     Document Type: Article

References (49)

1. + current: differential sensitivity lo block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
2. Backx PH, Marban E. Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes. Circ Res. 1993;72:890-900.
3. Kass RS, Freeman LC. Potassium channels in the heart: cellular, molecular and clinical implications. Trends Cardiovasc Med. 1993;3:149-159.
4. Vaughan-Williams EM. Classification of anti-dysrhythmic drugs. Pharmacol Ther. 1975;1:115-138.
5. Colatsky TJ, Argentieri TM. Potassium channel blockers as antiarrhythmic drugs. Drug Dev Res. 1994;33:235-249.
6. + current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol. 1992;20:S106-S113.
7. KI, blockade is unlikely to be a potentially useful antiarrhythmic mechanism. Cardiovasc Res. 1994;28:420. Controversy.
8. KI blockade is a potentially useful antiarrhythmic mechanism. Cardiovasc Res. 1994;28:421. Controversy.
9. KI blockade: a new antiarrhythmic mechanism? Effect of RP 58866 on ventricular arrhythmias in rat. rabbit, and primate. Circulation. 1993;87:1979-1989.
10. Martin CL, Chinn K. Contribution of delayed rectifier and inward rectifier to repolarization of the action potential: pharmacologic separation. J Cardiovasc Pharmacol. 1992;19:830-837.
11. Nakayama T, Kurachi Y, Noma A, Irisawa H. Action potential and membrane currents of single pacemaker cells of the rabbit heart. Pflugers Arch. 1984;402:248-257.
12. Steinhelper ME, Lanson NA Jr, Dresdner KP, Delcarpio JB, Wit AL, Claycomb WC, Field LJ. Proliferation in vivo and in culture of differentiated adult atrial cardiomyocytes from transgenic mice. Am J Physiol. 1990;259:H1826-H1834.
13. + channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Cm- Res. 1994;75:870-878.
14. Kr potassium channel. Cell. 1995;81:299-307.
15. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. J Pharmacol Exp Ther. 1995;76:110-119.
16. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ Jr, Baskin EP, Lynch JJ Jr, Salata JJ. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol. 1995;26:259-271.
17. Delcarpio JB, Lanson NA Jr, Field LJ, Claycomb WC. Morphological characterization of cardiomyocytes isolated from a transplantable cardiac tumor derived from transgenic mouse atria (AT-1 cells). Circ Res. 1991;69:1591-1600.
18. Kr,) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation. 1995;91:1799-1806.
19. + current by dofetilide. Circ Res. 1993;72:75-83.
20. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992;262:809-817.
21. + currents. Pflugers Arch. 1992;420:180-186.
22. Liu Y, Taffet SM, Anumonwo JMB, Delmar M. Characterization of an E-4031-sensitive potassium current in quiescent AT-1 cells. J Cardiovasc Electrophysiol. 1994;5:1017-1030.
23. + channel: open-channel block by methanesulfonanilides. Circ Res. 1996;78:499-503.
24. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269:92-95.
25. Ks contributes to the longer action potential of the M cell. Circ Res. 1995;76:351-365.
26. Balser JR, Bennett PB, Roden DM. Time-dependent outward current in guinea pig ventricular myocytes: gating kinetics of the delayed rectifier. J Gen Physiol. 1990;96:835-863.
27. K, by cadmium in eat ventricular myocytes. Am J Physiol. 1992;262:C75-C83.
28. 2+ in guinea pig ventricular myocyles. Am J Physiol. 1991;261:C23-C31.
29. + current is composed of two currents in guinea pig atrial cells. Am J Physiol. 1991;260:H393-H399.
30. McLarnon JG, Xu R. Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes. J Pharmacol Exp Ther. 1995;275:389-396.
31. Yang T, Tande PM, Lathrop DA, Refsum H. Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea pig papillary muscle. Cardiovasc Drugs Ther. 1992;6:429-436.
32. Veldkamp MW, van Ginneken ACG, Bouman LN. Delayed rectifier channel open probability during diastolic depolarization in sinoatrial node cells. Biophys J. 1996;70:A188. Abstract.
33. Beregi JP, Escande D, Coudray N, Mery P, Mestre M, Chemla D, LeCarpentier Y. Positive inotropic effects of RP 62719, a new pure class III antiarrhythmic agent, on guinea pig myocardium. J Pharmacol Exp Ther. 1992;263:1369-1376.
34. Baskin EP, Serik CM, Wallace AW, Brookes LM, Selnick HG, Claremon DA, Lynch JJ Jr. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol. 1991;18:406-414.
35. Shimoni Y, Clark RB, Giles WR. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. J Physiol. 1992;448:709-727.
36. Kass RS, Arena JP, Walsh KB. Measurement and block of potassium channel currents in the heart: importance of channel type. Drug Dev Res. 1990;19:115-127.
37. Nichols CG, Makhina EN, Pearson WL, Sha Q, Lopatin AN. Inward rectification and implications for cardiac excitability. Circ Res. 1996;78:1-7.
38. + channel in human cardiac myocytes: alterations in channel behavior in myocytes isolated from patients with idiopathic dilated cardiomyopathy. Circulation. 1995;92:164-174.
39. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res. 1993;73:379-385.
40. + current during the action potential of guinea pig ventricular myocytes. Biophys J. 1991;60:1534-1539.
41. Delmar M, Ibarra J, Davidenko J, Lorente P, Jalife J. Dynamics of the background outward current of single guinea pig ventricular myocytes: ionic mechanisms of hysteresis in cardiac cells. Circ Res. 1991;69:1316-1326.
42. Kiyosue T, Arita M. Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ Res. 1989;64:389-397.
43. Kr, channel. J Gen Physiol. 1996;107:611-619.
44. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERO cardiac potassium channel. Nature. 1996;379:833-836.
45. Lynch JJ Jr, Wallace AA, Stupienski RF III, Baskin EP, Beare CM, Appleby SD, Salata JJ, Jurkiewicz NK, Sanguinetti MC, Stein RB, Gehret JR, Kothstein T, Claremon DA, Elliot JM, Butcher JW, Remy DC, Baldwin JJ. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. J Pharmacol Exp Ther. 1994;269:541-554.
46. sK in guinea pig cardiac myocytes. Biochem Biophys Res Commun. 1994;202:265-270.
47. + currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther. 1990;254:560-569.
48. + current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992;262:99-108.
49. Kr, and effects on myocardial refractoriness for class 111 antiarrhythmic agents. J Cardiovasc Pharmacol. 1995;25:336-340.